Outcome of care for home management with intensive input in adult CF patients during pulmonary exacerbations (PExs) – a comparative prospective study with hospital care  by Sequeiros, I.M. & Jarad, N.A.
S58 7. Pulmonology
223 Outcome of care for home management with intensive input
in adult CF patients during pulmonary exacerbations (PExs) −
a comparative prospective study with hospital care
I.M. Sequeiros1, N.A. Jarad1. 1University Hospitals Bristol NHS Trust, Department
of Respiratory Medcine, Bristol, United Kingdom
Background: Evidence of an inferior outcome of care for patients treated at home
in comparison with those treated in hospital is a cause for concern. Reasons for the
poorer outcome include reduced support at home from the multidisciplinary team
(MDT) in comparison to hospital care. A new intensive home treatment service was
organised mimicking hospital care, in which patients on IV treatment are visited
at home twice weekly by a CF physiotherapist and nurse, who assess patients,
spirometry and weight, reinforce compliance, the importance of rest and good diet.
Patients and Methods: We prospectively compared the outcome of PExs treated
with intensive home input by the MDT with that of hospital care and of the standard
home care without intensive assistance. Treatment site was decided as a consensus
between the MDT and the patient. Outcome measures analysed were changes in
spirometry, weight and symptom score from day 1 to day 14 of treatment and time
until the next PEx needing IV treatment.
Results: 180 PExs in 58 patients were analysed. There were no differences in age,
gender or baseline spirometry between the groups, but baseline BMI was higher
in the new home service group (P = 0.008). FEV1 and BMI improvement were
signiﬁcantly greater in the hospital group in comparison to the home with input
group (P = 0.01 and P = 0.02 respectively) and with the standard home group (P=
0.02 for FEV1 and P = 0.03 for BMI). The time until the next PEx was similar in
all groups.
Conclusions: Despite extensive efforts to improve home treatment, outcome mea-
sures remained better for those treated in hospital. The impact of this study is
important for the organisation of care of CF exacerbations.
224 Predictors of the time until the next pulmonary exacerbation in
adult CF patients
I.M. Sequeiros1, N.A. Jarad1. 1University Hospitals Bristol NHS Trust, Department
of Respiratory Medicine, Bristol, United Kingdom
Introduction: Acute infective pulmonary exacerbation (PEx) is an important feature
of CF. PExs are common and associated with impaired quality of life and accelerated
decline in lung function. It is therefore goals of optimal CF management not only
the treatment of such infections, but also the prevention of PExs and to increase the
time between exacerbations. We aimed to assess factors associated with a shorter
time until the following PEx.
Patients and Methods:We prospectively analysed 181 PExs in 58 adult CF patients
(32 male, mean age 26 years) treated with intravenous (IV) antibiotics. PExs were
methodically diagnosed according to a combination of subjective and objective
parameters. Outcome measures on day 14 of treatment were documented, including
FEV1, FVC, PEFR, FEF25−75, BMI, C reactive protein (CRP) and symptom score
(SS). The days until the following PEx needing IV antibiotics were calculated.
Results: Lower spirometry values at the end of PExs were associated with shorter
times until the following exacerbation, P< 0.001 for FEV1, FVC and PEFR. Higher
symptom scores were also associated with shorter times until the following PEx
(P = 0.02). Measurement of small airway disease (FEF25−75), CRP and BMI at the
end of treatment of PEx did not predict the time until the following exacerbation.
Conclusions: Poorer lung function tests and greater symptoms were associated with
a shorter time until the following PEx. BMI and CRP measurements did not predict
the time until the following PEx. These results have an impact on the outlook of
patients when planning their care in CF centres.
225 Symptomatic sinus disease in cystic ﬁbrosis and its effect on
lung function
I. Shaﬁq1, T.W.V. Daniels1, M.P. Carroll1, J.A. Nightingale1. 1Southampton
General Hospital, Adult Cystic Fibrosis Unit, Southampton, United Kingdom
Introduction: Structural and functional abnormalities of sinuses are common in
CF but not all patients are symptomatic. It is thought that sinus disease may be
associated with increased lower respiratory tract pathology.
Methods: From our cohort of adult CF patients we identiﬁed patients labelled to
have symptomatic sinus disease at annual review. We obtained following data from
Port CF: baseline FEV1, decline in FEV1 over 1 year, sputum microbiology and
presence or absence of ABPA. Full data was available for 106 patients.
Results: We identiﬁed 50 patients with symptomatic sinus disease and 56 patients
without. The baseline characteristics are shown in the table. The baseline FEV1
was statistically greater in the symptomatic group compared with asymptomatic
(2.34 vs. 1.92). There was a trend towards greater deterioration in FEV1 in
symptomatic group.
Baseline characteristics and results
Sinus disease Total (%)
Symptomatic (%) Asymptomatic (%)
n 50 (47.17) 56 (52.83) 106
Male 23 (46) 29 (51.78) 52
Female 27 (54) 27 (48.22) 54
Mean age 29.62 29.07 29.34
Mean FEV1 2.34 1.92, p = 0.019 2.13
Drop in FEV1 0.20 (8.78) 0.06 (3.3), p = 0.064 0.13 (6.31)
Pseudomonas 40 (80) 50 (89.2) 90 (84.9)
NTM 5 (10) 1 (1.78) 6 (5.66)
ABPA 4 (8) 10 (17.85) 14 (13.2)
Discussion: These results show that symptomatic sinus disease is associated with
less severe lung disease. Other investigators have previously shown that patients
with visible nasal polyps have better lung function than age matched peers. Larger
studies are needed.
226 Obstructive sleep apnea and nocturnal hypoventilation in adults
and children with cystic ﬁbrosis
C. Sciuto1, L. Spicuzza1, L. Tardino1, L.R. Mario1. 1UO Broncopneumologia
Pediatrica, Dip di Pediatria, Catania, Italy
Chronic airway obstruction may determine early hypoxaemia during exercise and
sleep even in patients with normal diurnal blood gases. The aim of our study
was to establish the occurrence of sleep-disordered breathing (SDB) in a cohort
of patients with cystic ﬁbrosis (CF), followed in our Cystic Fibrosis Unit. We
therefore studied 55 patients (49% M; 36% children (mean age 4.3±3.9, SaO2
% awake 97.7±1.5); 64% adults (mean age 20.9±4.9, BMI 21.1±3.6, SaO2 %
awake 97.1±1.1). All patients, in stable clinical conditions, underwent a nocturnal
standard polysomnography (sleep monitoring system Compumedics S-Series) and
respiratory functional evaluation during the day. Scoring of respiratory events was
performed according to standard criteria. Polysomnographic monitoring revealed the
occurrence of SDB, deﬁned as an apnea-hypopnea index (AHI)> 5, in 52% of adults
and in 56% of children. In adults we found mean AHI 16.8±7.8, mean nocturnal
SaO2 93.9%±2.3, mean SaO2 min 88.2%±2.2; in children we found mean AHI
12.5±5.8, mean nocturnal SaO2 93.7%±1.2, mean SaO2 min 89.2%±3.2. In both
adults and children we found a similar prevalence of upper airways obstruction
(sinusitis and rhinitis), a major cause of SDB, in groups with SDB and without
SDB. In adults we found a lower mean FEV1% in the group with SDB as compared
to the group without SDB (50% vs 64%, respectively).
These data show an high prevalence of sleep-disordered breathing in patients with
cystic ﬁbrosis. In these patients SDB occurs in an early phase of life and in
adulthood SDB seems to be associated to a lower respiratory function.
